NeurAxis Stock Rallies 26% as Adoption of Drug-Free IB-Stim Technology to Treat Pediatric FAP/IBS Gains Momentum ($NRXS)
NeurAxis Inc. stock is in rally mode, jumping over 26% since last week. Despite this significant increase, investors following this innovative biotech anticipate further growth. That optimism is...
Source: marketscreener.com